Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Identify which tilts (such as value or quality) tend to be more tax-efficient in retirement index funds and how these choices affect after-tax performance and risk.
24,606 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
The White House extended the deadline for Iran to reopen the Strait of Hormuz to April 6, sparking a fresh wave of oi...
A fast-growing tech name in the AI space has dazzled investors, but a recent funding move underscored a crucial risk....
Grocery prices are quietly reshaping how families spend and how lenders price risk. In this guide, learn why the next...
AI demand is lifting the semiconductor sector to new highs. This guide highlights two strong chip stocks to buy now, ...
A surge in AI-focused hardware stocks has lifted semiconductors, yet traders warn that the moment when semi trade tur...
CME marks a year since launching XRP futures, with notional volume around $63 billion as of mid-May 2026. The platfor...
Anthropic, the Claude-maker, confidentially files to go public, igniting talk of a potential trillion-dollar valuatio...
A deep dive into applied digital's stunning rally, the backlog fueling demand, and the tough questions investors must...
Oil prices are falling, delivering relief to some budgets, but the Fed's decision to hold rates could keep mortgage c...
The AI hardware boom is fading as demand cools, dragging optical and memory stocks lower and prompting investors to r...
Bitcoin climbed past key levels as soft U.S. payroll data cooled rate-hike expectations. Yet traders remain hedged, w...